PubMed

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.

Diabetes Care. 2009 Mar;32(3):493-8. Epub 2008 Nov 4.PMID: 18984774 [PubMed - indexed for MEDLINE]Related articlesFree article

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.PMID: 16259526 [PubMed - indexed for MEDLINE]Related articles

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators.

Cardiovasc Diabetol. 2005 Aug 22;4:13.PMID: 16111499 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420. PMID: 16310551 [PubMed - indexed for MEDLINE]Related articles

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Keating GM, Croom KF.

Drugs. 2007;67(1):121-53. Review.PMID: 17209672 [PubMed - indexed for MEDLINE]Related articles

The role of fenofibrate in clinical practice.

Zambon A, Cusi K.

Diab Vasc Dis Res. 2007 Sep;4 Suppl 3:S15-20.PMID: 17935056 [PubMed - indexed for MEDLINE]Related articles

More clinical lessons from the FIELD study.

Fazio S.

Cardiovasc Drugs Ther. 2009 Jun;23(3):235-41. Review.PMID: 19160032 [PubMed - indexed for MEDLINE]Related articles

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators.

Lancet. 2009 May 23;373(9677):1780-8.PMID: 19465233 [PubMed - indexed for MEDLINE]Related articlesFree article

A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?

Steiner G.

Treat Endocrinol. 2005;4(5):311-7. Review.PMID: 16185099 [PubMed - indexed for MEDLINE]Related articles

Increasing high-density lipoprotein cholesterol: an update on fenofibrate.

Després JP.

Am J Cardiol. 2001 Dec 20;88(12A):30N-36N. Review.PMID: 11788128 [PubMed - indexed for MEDLINE]Related articles

Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.

Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson PW.

Diabetes Care. 2007 May;30(5):1219-25. Epub 2007 Jan 26.PMID: 17259468 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS.

Curr Med Res Opin. 2005 Dec;21(12):1997-2006.PMID: 16368051 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.

Davidson MH, Bays H, Rhyne J, Stein E, Rotenberg K, Doyle R.

Clin Ther. 2005 Jun;27(6):715-27.PMID: 16117978 [PubMed - indexed for MEDLINE]Related articles

Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes.

Guzder RN, Gatling W, Mullee MA, Byrne CD.

Diabetologia. 2006 Jan;49(1):49-55. Epub 2005 Dec 10.PMID: 16341841 [PubMed - indexed for MEDLINE]Related articles

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, Taskinen MR.

Diabetologia. 2007 Oct;50(10):2067-75. Epub 2007 Jul 26. Erratum in: Diabetologia. 2007 Dec;50(12):2611-3. PMID: 17653691 [PubMed - indexed for MEDLINE]Related articles

Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.

Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z.

Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7.PMID: 15124979 [PubMed - indexed for MEDLINE]Related articles

[The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis]

Rosolová H, Bláha V, Ceska R, Hamouz Z, Pelikánová T, Soska V, Soucek M, Sucharda P.

Vnitr Lek. 2007 Apr;53(4):339-46. Czech. PMID: 17578163 [PubMed - indexed for MEDLINE]Related articles

FIELDS of dreams, fields of tears: a perspective on the fibrate trials.

Wierzbicki AS.

Int J Clin Pract. 2006 Apr;60(4):442-9. Review.PMID: 16620358 [PubMed - indexed for MEDLINE]Related articles

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW.

Diabetes Care. 2007 Aug;30(8):1945-51. Epub 2007 May 4.PMID: 17483155 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic syndrome in nondiabetic, obese, first-degree relatives of African American patients with type 2 diabetes: African American triglycerides-HDL-C and insulin resistance paradox.

Meis SB, Schuster D, Gaillard T, Osei K.

Ethn Dis. 2006 Autumn;16(4):830-6.PMID: 17061734 [PubMed - indexed for MEDLINE]Related articles